Sandeep Laumas, Executive Chairman at INNOVATE BIOPHARMACEUTICALS, INC. (INNT), bought 250 shares at $4.90 ($1K) on 2018-08-28, disclosed to the SEC on 2018-08-30.
Open-market purchase of $1k INNT by Executive Chairman. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| INNT | BUY | 2019-06-17 | $1K | — | Filing → |
| INNT | BUY | 2019-05-23 | $7K | — | Filing → |
| INNT | BUY | 2018-12-03 | $8K | — | Filing → |